Irinotecán Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecán Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, where it interferes with tumor DNA replication.

GNH USA supplies Irinotecán Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is indicated for colorectal cancer and related metastatic disease, acting within the chemotherapy regimen.

Metastatic colorectal cancer: improves overall survival when combined with fluorouracil and leucovorin. Advanced colorectal cancer: reduces tumor progression as part of combination therapy. Colorectal cancer refractory to first‑line treatment: provides an alternative therapeutic option.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness during treatment. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or bowel perforation from intense diarrhea. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver dysfunction. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Electrolyte disturbances: severe hypokalemia or hyponatremia.

Prior to initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dose in hepatic impairment. Maintain hydration: ensure adequate fluid intake to mitigate severe diarrhea. Avoid strong CYP3A4 inhibitors: concurrent use may increase exposure to SN‑38. Pregnancy considerations: use only if potential benefits justify potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise SN‑38 levels. - UGT1A1 inhibitors (e.g., atazanavir): increase risk of toxicity. - Concurrent myelosuppressive agents: amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Warfarin: monitor INR as irinotecan can affect coagulation. - Other antineoplastic agents: adjust dosing and monitor overlapping toxicities.